Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25358028 | 1.00 | CPN1 (0.58) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL2749798 | 1.00 | CPN1 (0.58) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL2268358 | 0.89 | SLC6A1 (0.53) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL25661085 | 0.89 | SLC6A1 (0.53) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL2268353 | 0.89 | SLC6A1 (0.53) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL30849133 | 0.89 | CPN1 (0.50) | CPN1CPB2GABRA5GABRB2SLC6A1 | |
| SCHEMBL2380451 | 0.85 | — | — | |
| SCHEMBL75669 | 0.85 | — | — | |
| SCHEMBL75670 | 0.85 | — | — | |
| SCHEMBL1797702 | 0.84 | CPN1 (0.49) | CPN1CPB2GABRA5GABRB2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | claimed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | claimed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | claimed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | claimed |
| CN-101107264-A | C5a receptor antagonists | JERINI AG (DE) | 2008-01-16 | — | — | CN | claimed |
| JP-2007534619-A | — | — | 2007-11-29 | — | — | JP | claimed |
| EP-1838725-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20060183883-A1 | C5a Receptor antagonists | JERINI AG (DE) | 2006-08-17 | — | — | US | claimed |
| WO-2006074964-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-07-20 | — | — | WO | claimed |
| EP-1646643-A2 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2006-04-19 | — | — | EP | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005010030-A2 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2005-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | CPN1 3127/4885CPB2 943/4885GABRA5 556/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | CPN1 3127/4885CPB2 943/4885GABRA5 556/4885 |
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | CPN1 2110/4885CPB2 2863/4885GABRA5 94/4885 |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | CPN1 3127/4885CPB2 943/4885GABRA5 556/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | CPN1 2214/4885CPB2 2496/4885GABRA5 830/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | CPN1 3127/4885CPB2 943/4885GABRA5 556/4885 |
| US-20060183883-A1 | C5a Receptor antagonists | C5AR1, C3AR1, C5AR2 | CPN1 705/4885CPB2 1691/4885GABRA5 290/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CPN1 303/4885CPB2 211/4885GABRA5 2359/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | CPN1 3127/4885CPB2 943/4885GABRA5 556/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | CPN1 574/4885CPB2 514/4885GABRA5 97/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | CPN1 574/4885CPB2 514/4885GABRA5 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.